die m.E bessere chancen bieten. Novel Drug Active in Anti-PD-1/L1 Resistant Tumors
Clinical benefit in almost half of patients with advanced NSCLC
A novel immunomodulatory therapy demonstrated antitumor activity ................
Overall, 31 patients had received prior immunotherapy, including all 13 patients with NSCLC
In addition to the 13 patients with NSCLC, the phase I study population comprised seven patients with melanoma, seven with ovarian cancer, four with breast cancer, and three with colorectal cancer. Overall, 15 unique tumor types were represented in the cohort, said Tolcher. The NSCLC subgroup accounted for all of the objective responses. The complete response began as a partial response at week 8 and became a complete response at week 32. All 13 patients in this subgroup had PD-1/L1-refractory disease. Disease control rate for these patients was 46%. Beyond the NSCLC subgroup, single-agent NC318 led to durable stable disease in patients with endometrial cancer, ovarian cancer, squamous cell carcinoma, Merkel cell carcinoma, and head and neck cancer.
|
Thread abonnieren
